PCSK9 deficiency has been shown to improve the survival rate of CVD patients, while gain- and loss-of-function mutations in PCSK9 have significant effects on hyper- or hypocholesterolemia in individuals and impact the development of ASCVD [14]. Here, PCSK9 is linked to Hypocholesterolemia.